Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study-Reference-Cited by-同舟云学术

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

Published:2021-08 Issue:8 Volume:9 Page:491-501
ISSN:2213-8587
Container-title:The Lancet Diabetes & Endocrinology
language:en
Short-container-title:The Lancet Diabetes & Endocrinology

Author:

Subbiah Vivek,Hu Mimi I,Wirth Lori J,Schuler Martin,Mansfield Aaron S,Curigliano Giuseppe,Brose Marcia S,Zhu Viola W,Leboulleux Sophie,Bowles Daniel W,Baik Christina S,Adkins Douglas,Keam Bhumsuk,Matos Ignacio,Garralda Elena,Gainor Justin F,Lopes Gilberto,Lin Chia-Chi,Godbert Yann,Sarker Debashis,Miller Stephen G,Clifford Corinne,Zhang Hui,Turner Christopher D,Taylor Matthew H

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference28 articles.

1. Medullary thyroid carcinoma: The third most common thyroid cancer reviewed;Stamatakos;Oncol Lett,2011

2. Novel rearrangements involving the RET gene in papillary thyroid carcinoma;Staubitz;Cancer Genet,2019

3. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma;Wells;Thyroid,2015

4. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases;Roman;Cancer,2006

5. RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients;Kato;Clin Cancer Res,2017

Cited by 234 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fundamentals and recent advances in the evaluation and management of medullary thyroid carcinoma;Molecular and Cellular Endocrinology;2024-10

2. Efficacy and safety of pralsetinib in patients with RET fusion positive non–small cell lung cancer: An observational real world study;Lung Cancer;2024-10

3. The Sirt1/Nrf2 pathway is a key factor for drug therapy in chemotherapy-induced cardiotoxicity: a Mini-Review;Medical Oncology;2024-09-11

4. Predictive biomarkers in thyroid cancer in the current molecular-morphology paradigm;Surgical and Experimental Pathology;2024-08-14

5. Recent advances in the use of tyrosine kinase inhibitors against thyroid cancer;Expert Opinion on Pharmacotherapy;2024-08-12